Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiora Pharmaceuticals (KPRX) Shares Outstanding (Weighted Average) (2016 - 2025)

Kiora Pharmaceuticals' Shares Outstanding (Weighted Average) history spans 11 years, with the latest figure at $4.2 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 7.59% year-over-year to $4.2 million; the TTM value through Dec 2025 reached $4.2 million, up 7.59%, while the annual FY2025 figure was $4.2 million, 7.59% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $4.2 million in Q4 2025 per KPRX's latest filing, down from $4.3 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $13.1 million in Q2 2022 to a low of $241099.0 in Q4 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $3.4 million, with a median of $3.5 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding (Weighted Average): plummeted 97.8% in 2023, then soared 1129.81% in 2024.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $241099.0 in 2021, then soared by 108.39% to $502436.0 in 2022, then grew by 7.08% to $538007.0 in 2023, then soared by 619.81% to $3.9 million in 2024, then increased by 7.59% to $4.2 million in 2025.
  • Per Business Quant, the three most recent readings for KPRX's Shares Outstanding (Weighted Average) are $4.2 million (Q4 2025), $4.3 million (Q3 2025), and $4.0 million (Q2 2025).